Find the right fit for you - faster
Get tailored insights about working at ChemPartner in one quick step.
ChemPartner Snapshot
ShangPharma eschews traditional Eastern medicine. The contract research organization (CRO) assists US and international pharmaceutical and biotechnology companies with developing viable drug candidates. ShangPharma operates through a handful of subsidiaries, including ChemPartner, ChemExplorer, and PharmaExplorer. Its outsourced services include discovery chemistry, discovery biology and preclinical development, pharmaceutical development, and biologics services. ShangPharma has more than 150 customers; its top two, Eli Lilly and GlaxoSmithKline, together account for more than 25% of revenues. In 2010 the company filed to go public in the US with a $110 million initial public offering (IPO).
